Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + irinotecan + platinum + apatinib
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen is a sequential therapy being investigated for the treatment of untreated advanced or extensive-stage small cell lung cancer (SCLC). The protocol, primarily studied at Peking Union Medical College Hospital (NCT04453930), involves an induction phase of camrelizumab (an anti-PD-1 antibody), irinotecan (a topoisomerase I inhibitor), and a platinum agent (cisplatin or carboplatin), followed by a maintenance phase of camrelizumab and apatinib (a VEGFR-2 tyrosine kinase inhibitor). This approach combines immune checkpoint inhibition, cytotoxic chemotherapy, and anti-angiogenic therapy to target multiple pathways in SCLC progression.
- Other names
- Camrelizumab + Irinotecan + Platinum + ApatinibSequential Therapy of Camrelizumab Combined With Chemotherapy (Irinotecan Plus Platinum) and With Apatinib
02
Targets
DNATOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on camrelizumab + irinotecan + platinum + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + irinotecan + platinum + apatinib.